The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Forest Laboratories (Inst); GE Healthcare (Inst); Gilead Sciences (Inst); Janssen Scientific Affairs (Inst); Novartis (Inst); Pfizer (Inst); Sunovion (Inst); Teva (Inst); UCB (Inst); Ultragenyx Pharmaceuticals (Inst); Vertex (Inst)
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Forest Laboratories (Inst); GE Healthcare (Inst); Gilead Sciences (Inst); Janssen Scientific Affairs (Inst); Novartis (Inst); Pfizer (Inst); Sunovion (Inst); Teva (Inst); UCB (Inst); Ultragenyx Pharmaceuticals (Inst); Vertex (Inst)
Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-naïve anaplastic lymphoma kinase-positive (ALK+) advanced or metastatic non-small cell lung cancer (NSCLC): An adjusted indirect comparison.
 
Daniel Shao-Weng Tan
Consulting or Advisory Role - Boehringer Ingelheim; Novartis
Research Funding - Novartis (Inst)
 
Antonio Araujo
Consulting or Advisory Role - Astellas Pharma; Bayer; Hospira; Lilly
Speakers' Bureau - Astellas Pharma; AstraZeneca; Lilly
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Lilly
 
Jie Zhang
Employment - Daiichi Sankyo (I); Novartis
Stock and Other Ownership Interests - Daiichi Sankyo (I); Novartis
 
James E. Signorovitch
No Relationships to Disclose
 
Zheng-Yi Zhou
Consulting or Advisory Role - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Forest Laboratories (Inst); GE Healthcare (Inst); Genentech (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Shire (Inst)
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Forest Laboratories (Inst); GE Healthcare (Inst); Genentech (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Shire (Inst)
 
Xiaopeng Cai
Consulting or Advisory Role - Abbvie (Inst); Acorda Therapeutics (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Forest Laboratories (Inst); GE Healthcare (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Shire (Inst); Takeda (Inst); UCB (Inst)
Research Funding - Abbvie (Inst); Acorda Therapeutics (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Forest Laboratories (Inst); GE Healthcare (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Shire (Inst); Takeda (Inst); UCB (Inst)
 
Geoffrey Liu
No Relationships to Disclose